Pfizer Plans to Submit EUA Application for its COVID-19 Vaccine in Late November
Pfizer CEO Albert Bourla, DVM, PhD, posted a letter on the company’s website noting that the Pfizer/BioNTech COVID-19 vaccine should be ready to apply for the United States Food and Drug Administration’s (FDA) Emergency Use Authorization (EUA) by the third week of November. The FDA requires at least 2 months of safety data on 50% of clinical trial participants before granting an EUA for any COVID-19 vaccine.
The Pfizer vaccine is based on synthetic messenger RNA (mRNA), a new technology that helps the body’s own immune system identify and then combat the novel coronavirus by copying its surface. Read more here.